High prevalence of cardiovascular risk factors in a western urban Turkish population: A community-based study;Batı ve kentsel bir Türk toplumunda kardiyovasküler risk etmenlerinin yüksek prevalansı: Toplum tabanlı bir çalışma:

Anadolu Kardiyoloji Dergisi

Volumn 13, Issue 1, 2013, Pages 9-17

  Ünal, Belgin ^a   Sözmen, Kaan ^b   Uçku, Reyhan ^a   Ergör, Gül ^a   Soysal, Ahmet ^a   Baydur, Hakan ^a   Meseri, Reci ^c   Şimşek, Hatice ^a   Gerçeklioǧlu, Gül ^a   Doǧanay, Sinem ^a   Budak, Refik ^a   Kiliç, Bülent ^a   Günay, Türkan ^a   Ergör, Alp ^a   Demiral, Yücel ^a   Aslan, Özgür ^a   Çimrin, Dilek ^a   Akvardar, Yildiz ^a   Tuncel, Pinar ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b MINISTRY OF HEALTH   (Turkey)

^c EGE UNIVERSITY   (Turkey)

Author keywords

Coronary heart disease; Diabetes mellitus; Framingham risk score; Obesity; Prevalence; Smoking

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE DISTRIBUTION; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CARDIOVASCULAR RISK; CHI SQUARE TEST; CHOLESTEROL BLOOD LEVEL; COMMUNITY ASSESSMENT; DIABETES MELLITUS; FEMALE; FRAMINGHAM RISK SCORE; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; POPULATION RESEARCH; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; STUDENT T TEST; TURKEY (REPUBLIC); URBAN AREA;

EID: 84874539385     PISSN: None     EISSN: 13080032     Source Type: Journal    
DOI: 10.5152/akd.2013.002     Document Type: Article

References (40)

1. MoH. National burden of disease and cost effectiveness project final report. Ankara; 2004.
2. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S, Tolonen H, et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet 2000; 355: 675-87. [CrossRef]
3. Laatikainen T, Critchley J, Vartiainen E, Salomaa V, Ketonen M, Capewell S. Explaining the decline in coronary heart disease mortality in Finland between 1982 and 1997. Am J Epidemiol 2005; 162: 764-73. [CrossRef]
4. Tunstall-Pedoe H, Vanuzzo D, Hobbs M, Mahonen M, Cepaitis Z, Kuulasmaa K, et al. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. Lancet 2000; 355: 688-700. [CrossRef]
5. MoH. Prevention and Control Program for Cardiovascular Diseases: Strategic Plan and Action Plan for the Risk Factors Ankara: Ministry of Health; 2009.
6. Alwan A, Maclean DR, Riley LM, d'Espaignet ET, Mathers CD, Stevens GA, et al. Monitoring and surveillance of chronic noncommunicable diseases: progress and capacity in high-burden countries. Lancet 2010; 376: 1861-8. [CrossRef]
7. Ergör G, Soysal A, Sözmen K, Ünal B, Uçku R, Kiliç B, et al. Balcova heart study: rationale and methodology of the Turkish cohort. Int J Public Health 2011; 57: 535-42. [CrossRef]
8. Mancia G, De Backer G, Dominiczak A, Çifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87. [CrossRef]
9. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-63. [CrossRef]
10. Grundy SM. Metabolic syndrome scientific statement by the American Heart Association and the National Heart, Lung, and Blood Institute. Arterioscler Thromb Vasc Biol 2005; 25: 2243-4. [CrossRef]
11. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011; 34 Suppl 1: S62-9. [CrossRef]
12. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28: 2375-414. [CrossRef]
13. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47. [CrossRef]
14. van der Wilk EA, Jansen J. Lifestyle-related risks: are trends in Europe converging? Public Health 2005; 119: 55-66. [CrossRef]
15. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010; 121: e46-e215. [CrossRef]
16. BHF. Coronary heart disease statistics. Department of Public Health, University of Oxford; 2010.
17. Satman I, Yilmaz T, Şengul A, Salman S, Salman F, Uygur S, et al. Population-based study of diabetes and risk characteristics in Turkey: results of the turkish diabetes epidemiology study (TURDEP). Diabetes Care 2002; 25: 1551-6. [CrossRef]
18. MoH. Global Adult Tobacco Survey Turkey Report. Ankara: Ministry of Health, Primary Health Care general Directorate; 2010.
19. Satman I. TURDEP II: Initial Findings. In: Proceedings of the 13th National Public Health Congress, İzmir; 2010.
20. MoH. National Tobacco Control Programme and Action Plan Of Turkey 2008 - 2012 Ankara: Ministry of Health of Turkey; 2008.
21. Onat A. Lipids, lipoproteins and apolipoproteins among Turks, and impact on coronary heart disease. Anadolu Kardiyol Derg 2004; 4: 236-45.
22. T.C. Saǧli{dotless}k Bakanli{dotless}ǧi{dotless} Saǧli{dotless}kli{dotless} beslenelim, kalbimizi koruyali{dotless}m projesi araşti{dotless}rma raporu. Ankara: T.C Saǧli{dotless}k Bakanli{dotless}ǧi{dotless} Temel Saǧli{dotless}k Hizmetleri Genel Mudurluǧu, Gi{dotless}da Guvenliǧi Daire Başkanli{dotless}ǧi{dotless} Toplum Beslenmesi Şubesi; 2004.
23. Sanisoǧlu SY, Oktenli C, Hasimi A, Yokuşoǧlu M, Uǧurlu M. Prevalence of metabolic syndrome-related disorders in a large adult population in Turkey. BMC Public Health 2006; 6: 92. [CrossRef]
24. Onat A. Risk factors and cardiovascular disease in Turkey. Atherosclerosis 2001; 156: 1-10. [CrossRef]
25. Oǧuz A, Temizhan A, Abaci A, Kozan O, Erol C, Ongen Z, et al. Obesity and abdominal obesity; an alarming challenge for cardiometabolic risk in Turkish adults. Anadolu Kardiyol Derg 2008; 8: 401-6.
26. Motlagh B, O'Donnell M, Yusuf S. Prevalence of cardiovascular risk factors in the Middle East: a systematic review. Eur J Cardiovasc Prev Rehabil 2009; 16: 268-80. [CrossRef]
27. Wang Y, Mi J, Shan XY, Wang QJ, Ge KY. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obes (Lond) 2007; 31: 177-88. [CrossRef]
28. Welin L, Adlerberth A, Caidahl K, Eriksson H, Hansson PO, Johansson S, et al. Prevalence of cardiovascular risk factors and the metabolic syndrome in middle-aged men and women in Gothenburg, Sweden. BMC Public Health 2008; 8: 403. [CrossRef]
29. Danon-Hersch N, Marques-Vidal P, Bovet P, Chiolero A, Paccaud F, Pecoud A, et al. Prevalence, awareness, treatment and control of high blood pressure in a Swiss city general population: the CoLaus study. Eur J Cardiovasc Prev Rehabil 2009; 16: 66-72. [CrossRef]
30. Alkerwi A, Sauvageot N, Donneau AF, Lair ML, Couffignal S, Beissel J, et al. First nationwide survey on cardiovascular risk factors in Grand-Duchy of Luxembourg (ORISCAV-LUX). BMC Public Health 2010; 10: 468. [CrossRef]
31. Marrugat J, Subirana I, Comin E, Cabezas C, Vila J, Elosua R, et al. Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA Study. J Epidemiol Community Health 2007; 61: 40-7. [CrossRef]
32. Hense HW, Schulte H, Lowel H, Assmann G, Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany--results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 2003; 24: 937-45. [CrossRef]
33. Menotti A, Puddu PE, Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J 2000; 21: 365-70. [CrossRef]
34. Haq IU, Ramsay LE, Yeo WW, Jackson PR, Wallis EJ. Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high-risk men. Heart 1999; 81: 40-6.
35. Onat A, Can G, Hergenç G, Uǧur M, Yüksel H. Coronary disease risk prediction algorithm warranting incorporation of C-reactive protein in Turkish adults, manifesting sex difference. Nutr Metab Cardiovasc Dis 2012; 22: 643-50. [CrossRef]
36. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003. [CrossRef]
37. Tunstall-Pedoe H. The Dundee coronary risk-disk for management of change in risk factors. BMJ 1991; 303: 744-7. [CrossRef]
38. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002; 105: 310-5. [CrossRef]
39. WHO. WHO STEPS Surveillance manual. The WHO STEPwise approach to chronic disease risk factor surveillance. Geneva: World Health Organization; 2005.
40. WHO. Global status report on noncommunicable diseases 2010. Geneva: World Health Organisation; 2011.